NASDAQ · LNAI
Healthcare · Biotechnology
$2.22
Down-$0.02 (-0.89%)
Updated Aug 15, 2026, 2:06 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
LNAI closed at $2.22 after 21 trading sessions, down 21.28% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $2.25 | $2.25 | $2.15 | $2.22 | 33.78K |
| Aug 13, 2026 | $2.35 | $2.36 | $2.20 | $2.24 | 45.04K |
| Aug 12, 2026 | $2.39 | $2.41 | $2.26 | $2.35 | 218.63K |
| Aug 11, 2026 | $2.33 | $2.4727 | $2.33 | $2.40 | 30.5K |
| Aug 10, 2026 | $2.45 | $2.45 | $2.30 | $2.36 | 23.62K |
| Aug 7, 2026 | $2.40 | $2.55 | $2.39 | $2.41 | 37.65K |
| Aug 6, 2026 | $2.44 | $2.48 | $2.36 | $2.42 | 56.61K |
| Aug 5, 2026 | $2.51 | $2.75 | $2.3711 | $2.48 | 103.22K |
| Aug 4, 2026 | $2.16 | $3.20 | $2.1345 | $2.55 | 845.19K |
| Aug 3, 2026 | $2.0001 | $3.7799 | $1.91 | $2.39 | 8.1M |
| Jul 31, 2026 | $2.05 | $2.13 | $1.94 | $1.94 | 26.54K |
| Jul 30, 2026 | $2.06 | $2.105 | $2.00 | $2.02 | 23.55K |
| Jul 29, 2026 | $2.17 | $2.20 | $2.06 | $2.11 | 15.28K |
| Jul 28, 2026 | $2.22 | $2.31 | $2.22 | $2.24 | 12.15K |
| Jul 27, 2026 | $2.33 | $2.37 | $2.22 | $2.23 | 26.46K |
| Jul 24, 2026 | $2.39 | $2.52 | $2.32 | $2.33 | 13.32K |
| Jul 23, 2026 | $2.61 | $2.7532 | $2.31 | $2.32 | 30.28K |
| Jul 22, 2026 | $2.76 | $2.795 | $2.57 | $2.61 | 34.44K |
| Jul 21, 2026 | $2.73 | $3.09 | $2.65 | $2.76 | 48.2K |
| Jul 20, 2026 | $2.78 | $2.78 | $2.64 | $2.64 | 17.88K |
| Jul 17, 2026 | $2.85 | $2.8502 | $2.80 | $2.82 | 15.89K |
The latest Smart Investors Daily articles mentioning LNAI.
LNAI research
Company profile and research snapshot.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Mar 5, 2026
On February 27, 2026, Lunai Bioworks Inc. (the "Company") implemented a temporary furlough of its employees in the United States and Canada as part of actions intended to preserve the Company's liquidity while it
Benzinga · Feb 17, 2026
Lunai Bioworks Inc. - Common Stock (NASDAQ:LNAI) reported quarterly losses of $(0.08) per share. This is a 82.22 percent increase over losses of $(0.45) per share from the same period last year.
Benzinga · Feb 9, 2026
Benzinga · Feb 9, 2026
AI-driven analysis of Phase 2 survival and progression data aims to identify high-benefit patient subgroups and optimize future registrational trial strategySACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire/ -- Lunai Bioworks
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LNAI.
No results
No recent SID articles mention LNAI.
